Mainz Biomed

Mainz Biomed company information, Employees & Contact Information

Explore related pages

Related company profiles:

Mainz Biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. We develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. Visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.

Company Details

Employees
30
Address
Robert-Koch-Straße 50, Mainz,rhineland-Palatinate 55129,germany
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Mainz, Rhineland-Palatinate
Looking for a particular Mainz Biomed employee's phone or email?

Mainz Biomed Questions

News

Mainz Biomed to Attend 2025 Maxim Growth Summit - GlobeNewswire

Mainz Biomed to Attend 2025 Maxim Growth Summit GlobeNewswire

Oct 22-23, 2025 — Mainz Biomed at Maxim Growth Summit in NYC; one-on-one meetings with investors - Stock Titan

Oct 22-23, 2025 — Mainz Biomed at Maxim Growth Summit in NYC; one-on-one meetings with investors Stock Titan

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® - Yahoo Finance

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® Yahoo Finance

Mainz Biomed Secures Public Funding from ISB for Pancreatic Cancer Early Detection Project - Nasdaq

Mainz Biomed Secures Public Funding from ISB for Pancreatic Cancer Early Detection Project Nasdaq

Mainz Biomed to Present Innovative RNA-based Colorectal Cancer Screening Findings at World Endoscopy Organization Meeting - Quiver Quantitative

Mainz Biomed to Present Innovative RNA-based Colorectal Cancer Screening Findings at World Endoscopy Organization Meeting Quiver Quantitative

100% sensitivity: Mainz Biomed biomarker panel shows 95% specificity in 30‑patient pancreatic study - Stock Titan

100% sensitivity: Mainz Biomed biomarker panel shows 95% specificity in 30‑patient pancreatic study Stock Titan

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition - Yahoo Finance

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition Yahoo Finance

Mainz Biomed Launches ColoAlert® for Colorectal Cancer Screening in Switzerland - Quiver Quantitative

Mainz Biomed Launches ColoAlert® for Colorectal Cancer Screening in Switzerland Quiver Quantitative

Mainz Biomed Partners with CARE Diagnostica to Enhance Colorectal Cancer Screening in Germany - Nasdaq

Mainz Biomed Partners with CARE Diagnostica to Enhance Colorectal Cancer Screening in Germany Nasdaq

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland - GlobeNewswire

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland GlobeNewswire

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update Yahoo Finance

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland - Stock Titan

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland Stock Titan

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewswire

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project GlobeNewswire

97% Accuracy: Mainz Biomed's Revolutionary RNA Test Could Transform Early Colorectal Cancer Detection - Stock Titan

97% Accuracy: Mainz Biomed's Revolutionary RNA Test Could Transform Early Colorectal Cancer Detection Stock Titan

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom - GlobeNewswire

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom GlobeNewswire

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants GlobeNewswire

Mainz Biomed's ColoAlert® Receives MHRA Approval for UK Market Expansion - Quiver Quantitative

Mainz Biomed's ColoAlert® Receives MHRA Approval for UK Market Expansion Quiver Quantitative

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - Yahoo Finance

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study Yahoo Finance

Mainz Biomed Enters into Technology Partnership with EDX Medical Group - GlobeNewswire

Mainz Biomed Enters into Technology Partnership with EDX Medical Group GlobeNewswire

44,000 Annual Cancer Cases: Mainz Biomed's ColoAlert Test Gets UK Approval for Colorectal Screening - Stock Titan

44,000 Annual Cancer Cases: Mainz Biomed's ColoAlert Test Gets UK Approval for Colorectal Screening Stock Titan

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants GlobeNewswire

Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq

Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress Nasdaq

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Yahoo Finance

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test Yahoo Finance

Mainz Biomed Announces Stock Split - GlobeNewswire

Mainz Biomed Announces Stock Split GlobeNewswire

Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire

Mainz Biomed and Thermo Fisher Scientific Sign a GlobeNewswire

Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues - Stock Titan

Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues Stock Titan

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 GlobeNewswire

Mainz Biomed Announces Submission for FDA Breakthrough - GlobeNewswire

Mainz Biomed Announces Submission for FDA Breakthrough GlobeNewswire

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - Stock Titan

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 Stock Titan

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - Stock Titan

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Stock Titan

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel - Yahoo Finance

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel Yahoo Finance

Mainz Biomed and Bantleon Partner to Elevate Corporate - GlobeNewswire

Mainz Biomed and Bantleon Partner to Elevate Corporate GlobeNewswire

MYNZ - Mainz Biomed NV Latest Stock News & Market Updates - Stock Titan

MYNZ - Mainz Biomed NV Latest Stock News & Market Updates Stock Titan

Top Mainz Biomed Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant